Several US locations. Various Representatives.
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa
ID number: NCT03852472
Estimated Study Completion Date December 31, 2020
Information provided by (Responsible Party): ChemoCentryx
Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa
A receptor inhibitor acting like a biologic and an immunosuppressant and was developed for both auto-inflammatory and autoimmune illnesses. They also have expectations that Avacopan can be used as an alternative to corticosteroids. It inhibits the complement C5a receptor, or C5aR, for inflammatory diseases. Avacopan blocks the activity of complement C5a, a component of the complement system and the for C5aR.
For complete details for trial see link below:
Please understand as soon as they fill their recruiting quota these locations will become unavailable.
Several US locations. You can call the number below to see if your location is participating. Or view link provided. Type in Hidradenitis Suppurativa, your area and the miles in which you are willing to travel.
Contact: Jin Li 650-210-2986 jli@chemocentryx
Aurora pre-qualify link: